Doxycycline use in patients with lymphangioleiomyomatosis: Safety and efficacy in metalloproteinase blockade;Doxiciclina em pacientes com linfangioleiomiomatose: Segurança e eficácia no bloqueio de metaloproteinases

Jornal Brasileiro de Pneumologia

Volumn 37, Issue 4, 2011, Pages 424-430

  Pimenta, Suzana Pinheiro ^a   Baldi, Bruno Guedes ^a   Acencio, Milena Marques Pagliarelli ^a   Kairalla, Ronaldo Adib ^a   Carvalho, Carlos Roberto Ribeiro ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Doxycycline; Lymphangioleiomyomatosis; Matrix metalloproteinases

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; DOXYCYCLINE; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; DRUG ANTAGONISM; FEMALE; HUMAN; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; PATHOLOGY; PROSPECTIVE STUDY; URINE;

ADULT; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; DOXYCYCLINE; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MATRIX METALLOPROTEINASES; PROSPECTIVE STUDIES; PROTEASE INHIBITORS;

EID: 80052722004     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37132011000400003     Document Type: Article

References (28)

1. Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control. 2006;13(4):276-85.
2. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc. 2000;75(6):591-4.
3. Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151(2 Pt 1):527-33.
4. Chu SC, Horiba K, Usuki J, Avila NA, Chen CC, Travis WD, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest. 1999;115(4):1041-52.
5. Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax. 2000;55(12):1052-7.
6. Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173(1):105-11.
7. Aberle DR, Hansell DM, Brown K, Tashkin DP. Lymphangiomyomatosis: CT, chest radiographic, and functional correlations. Radiology. 1990;176(2):381-7.
8. Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA,etal. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2000;67(5):311-29.
9. Brentani MM, Carvalho CR, Saldiva PH, Pacheco MM, Oshima CT. Steroid receptors in pulmonary lymphangiomyomatosis. Chest. 1984;85(1):96-9.
10. Ji RC. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat Res Biol. 2006;4(2):83-100.
11. Fukuda Y, Kawamoto M, Yamamoto A, Ishizaki M, Basset F, Masugi Y. Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis. Hum Pathol. 1990;21(12):1252-61.
12. Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol. 1997;28(9):1071-8.
13. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000;124(2):267-75.
14. Odajima N, Betsuyaku T, Nasuhara Y, Inoue H, Seyama K, Nishimura M. Matrix metalloproteinases in blood from patients with LAM. Respir Med. 2009;103(1):124-9.
15. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006;354(24):2621-2.
16. Hayashi T, Rush WL, Travis WD, Liotta LA, Stetler-Stevenson WG, Ferrans VJ. Immunohistochemical study of matrix metalloproteinases and their tissue inhibitors in pulmonary Langerhans' cell granulomatosis. Arch Pathol Lab Med. 1997;121(9):930-7.
17. Colombat M, Caudroy S, Lagonotte E, Mal H, Danel C, Stern M, et al. Pathomechanisms of cyst formation in pulmonary light chain deposition disease. Eur Respir J. 2008;32(5):1399-403.
18. Vignola AM, Paganin F, Capieu L, Scichilone N, Bellia M, Maakel L,etal. Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J. 2004;24(6):910-7.
19. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58(7):1395-9.
20. Nelson ML. Chemical and biological dynamics of tetracyclines. Adv Dent Res. 1998;12(2):5-11.
21. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827-39.
22. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke. 2004;35(7):1715-9.
23. Fife RS, Sledge GW Jr. Effects of doxycycline on in vitrogrowth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med. 1995;125(3):407-11.
24. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 1991;51(2):672-5.
25. Chang WY, Clements D, Johnson SR. Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. Am J Physiol Lung Cell Mol Physiol. 2010;299(3):L393-400.
26. Yao JS, Shen F, Young WL, Yang GY. Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int. 2007;50(3):524-30.
27. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595-606.
28. Nurok M, Eslick I, Carvalho CR, Costabel U, D'Armiento J, Glanville AR, et al. The International LAM Registry:a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform. Lymphat Res Biol. 2010;8(1):81-7.